Macrophage activation syndrome associated with adult-onset Still's disease: a multicenter retrospective analysis

被引:40
|
作者
Wang, Ran [1 ]
Li, Ting [2 ]
Ye, Shuang [2 ]
Tan, Wenfeng [3 ]
Zhao, Cheng [4 ]
Li, Yisha [5 ]
de Bao, Chun [1 ]
Fu, Qiong [1 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Rheumatol, Shanghai 200001, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Rheumatol, South Campus, Shanghai 200001, Peoples R China
[3] Nanjing Med Univ, Affiliate Hosp 1, Dept Rheumatol, Nanjing 210000, Peoples R China
[4] Nanjing Univ, Med Sch, Affiliated Nanjing Drum Tower Hosp, Dept Rheumatol, Nanjing 210000, Peoples R China
[5] Cent South Univ, Xiangya Hosp, Dept Rheumatol, Changsha 410000, Peoples R China
关键词
Adult-onset Still's disease; Macrophage activation syndrome; Treatment; HEMOPHAGOCYTIC SYNDROME; OUTCOMES; PATIENT;
D O I
10.1007/s10067-020-04949-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To explore the clinical features, treatments, and prognostic factors of adult-onset Still's disease (AOSD)-associated macrophage activation syndrome (MAS), we conducted a multicenter retrospective clinical study of AOSD-associated MAS patients. Methods AOSD patients were collected from six tertiary hospitals in China. Medical charts were reviewed and clinical information was recorded and analyzed. Results There were 447 AOSD patients enrolled into this retrospective clinical study. Among them, 55 were diagnosed with MAS. Liver dysfunction was the most reliable predictive factor for the screening of MAS in AOSD patients (OR = 75.744, 95%CI = 23.015-249.284, p < 0.0001). In multivariate analysis, clinical features including platelets < 100 x 10(9)/L (OR = 9.546, p = 0.005), aspartate transaminase (AST) > 120 U/L (OR = 25.853, p < 0.0001), triglycerides > 3 mmol/L (OR = 12.9833, p = 0.011)), ferritin > 1500 ng/mL (OR = 5.513, p = 0.050), as well as hemophagocytosis in bone puncture (OR = 18.132, p = 0.001) were highly associated with the occurrence of MAS. The mortality rate of total AOSD patients was 4.47%, MAS was the main cause of death in AOSD patients (OR = 11.705, 95%CI = 4.783-28.647, p < 0.0001). PLT <= 100 x 10(9)/L (p = 0.0001), fibrinogen < 1.5 g/L (p = 0.0286), splenomegaly (p = 0.0002), and liver dysfunction (p = 0.0008) highly suggested poor prognosis. Conclusion MAS occurrence is the major cause of death in AOSD patients. Notable liver dysfunction, as well as splenomegaly, low number of platelets or neutrophils, high levels of serum ferritin, and reduced level of fibrinogen are risk factors for poor outcome.
引用
收藏
页码:2379 / 2386
页数:8
相关论文
共 50 条
  • [21] Latent class analysis of 216 patients with adult-onset Still's disease
    Sugiyama, Takahiro
    Furuta, Shunsuke
    Hiraguri, Masaki
    Ikeda, Kei
    Inaba, Yosuke
    Kagami, Shin-Ichiro
    Kita, Yasuhiko
    Kobayashi, Kei
    Kobayashi, Yoshihisa
    Kurasawa, Kazuhiro
    Nakagomi, Daiki
    Nawata, Yasushi
    Kawasaki, Yohei
    Shiko, Yuki
    Sugiyama, Takao
    Nakajima, Hiroshi
    ARTHRITIS RESEARCH & THERAPY, 2022, 24 (01)
  • [22] Adult-onset Still's disease complicated by macrophage activation syndrome during pregnancy: a case-based review
    Wise, Leanna
    Zell, Monica
    CLINICAL RHEUMATOLOGY, 2023, 42 (11) : 3159 - 3166
  • [23] Pregnancy-Associated Onset of Adult-Onset Still's Disease
    Zayat, Nawras
    Arora, Avish
    O'Brien, Joselle
    Bal, Japjot
    Sugarman, Rebekah
    Rivera, Leeshun
    Shamshirsaz, Amir
    Vani, Kavita
    Mastrogiannis, Dimitrios S.
    AJP REPORTS, 2024, 14 (02): : e145 - e155
  • [24] Short-term, low-dose etoposide in refractory adult-onset Still’s disease-associated macrophage activation syndrome
    Ran Wang
    Ting Li
    Shuang Ye
    Liangjin Lv
    Sheng Chen
    Xiaodong Wang
    Chun-de Bao
    Qiong Fu
    Clinical Rheumatology, 2022, 41 : 2817 - 2823
  • [25] Treatment of adult-onset still's disease: up to date
    Yoo, Dae Hyun
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (09) : 849 - 866
  • [26] Adult-onset Still's Disease Complicated With Hemophagocytic Syndrome
    Yeh, Horng-Ming
    Liu, Ming-Fei
    Chang, Kuo-Kuan
    Liu, Shian-Min
    Chen, Chang-Hung
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2010, 109 (01) : 85 - 88
  • [27] Adult-onset Still's disease
    Gerfaud-Valentin, Mathieu
    Jamilloux, Yvan
    Iwaz, Jean
    Seve, Pascal
    AUTOIMMUNITY REVIEWS, 2014, 13 (07) : 708 - 722
  • [28] Hemophagocytic syndrome in patients with adult-onset Still's disease: Diagnostic problems
    Zakharova, A. Yu.
    Mutovina, Z. Yu.
    Gordeev, A. V.
    Shestakova, I. N.
    TERAPEVTICHESKII ARKHIV, 2015, 87 (05) : 84 - 89
  • [29] Successful re-administration of tocilizumab in a patient with adult-onset Still's disease after improvement of macrophage activation syndrome
    Nagasawa, Yuma
    Takase-Minegishi, Kaoru
    Adachi, Soichiro
    Ichikawa, Kento
    Nagai, Hideto
    Watanabe, Tomoya
    Yamaguchi, Yukie
    Yoshimi, Ryusuke
    Kirino, Yohei
    Nakajima, Hideaki
    MODERN RHEUMATOLOGY CASE REPORTS, 2025,
  • [30] Are the 2016 EULAR/ACR/PRINTO classification criteria for macrophage activation syndrome applicable to patients with adult-onset Still's disease?
    Tada, Yoshifumi
    Inokuchi, Satomi
    Maruyama, Akihito
    Suematsu, Rie
    Sakai, Mariko
    Sadanaga, Yuri
    Ono, Nobuyuki
    Arinobu, Yojiro
    Koarada, Syuichi
    RHEUMATOLOGY INTERNATIONAL, 2019, 39 (01) : 97 - 104